

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Yes, in the "Methods" section of Main Text.	
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		n/a. No cell lines
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		n/a. No primary cultures.
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		n/a. No animal
Animal observed in or captured from the field: Provide species, sex and age where possible		n/a. No animal
Model organisms: Provide Accession number in repository (where relevant) OR RRID		n/a. No animal
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		n/a. No plants.
Microbes: provide species and strain, unique accession number if available, and source		n/a. No microbes.
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s)), provide reference number for approval.	Yes. In the "Methods" section of Main Text and the "Ethical Statement" section of Footnote.	
Provide statement confirming informed consent obtained from study participants.	Yes. In the "Methods" section of Main Text and the "Ethical Statement" section of Footnote.	
Report on age and sex for all study participants.	Yes. All participants are women and the age is in the "Table 1" of Main Text.	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.		n/a. Not clinical trial.
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		n/a. No detailed protocols.
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination		n/a
Randomisation		n/a
Blinding		n/a
Inclusion/exclusion criteria	Yes, in the “Methods” section of Main Text.	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Three times.	
Define whether data describe technical or biological replicates	biological replicates.	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes. In the “Methods” section of Main Text and the “Ethical Statement” section of Footnote.	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a. No experimental animals.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Yes. In the “Methods” section of Main Text and the “Ethical Statement” section of Footnote.	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		n/a.

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		n/a. No Attr itio n.
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Yes, in the "Methods" section of Main Text.	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		n/a. new ly crea ted dat aset s are una vail able
If data are publicly available, provide accession number in repository or DOI or URL.		n/a. dat a are not pub licly avai labl e
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		n/a. No reus ed dat a.
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		n/a. cod e or soft war e is una vail able
If code is publicly available, provide accession number in repository, or DOI or URL.		n/a. cod e are not pub

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.		

Article information: <http://dx.doi.org/10.21037/atm-20-1150>.